What the FDA Labels Say About Alcohol
The FDA prescribing information for Ozempic and Zepbound says nothing about drinking. We read both labels on DailyMed, the National Library of Medicine's label database. The only alcohol in either document is the benzyl alcohol listed as an inactive ingredient in Zepbound vials and the alcohol swab in the Ozempic pen instructions. There is no contraindication, no drink limit, and no instruction to abstain.
Silence is not a green light, though. Labels are built from trial evidence, and nobody ran a trial on semaglutide plus a Friday night out. The most useful guidance comes from the 2025 joint advisory on nutrition during GLP-1 therapy, published by the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. That advisory says alcohol may worsen nausea and gastroesophageal reflux with GLP-1 therapy and should be minimized. Minimized. Not banned. A glass of wine at a wedding and three drinks every night are different questions, and it is worth being honest with yourself about which one you are asking.
Where Alcohol and GLP-1s Overlap on Risk
Alcohol and GLP-1 medications cause trouble mostly by piling onto problems each can create alone, not through a chemical interaction that anyone has documented. Four overlaps are worth knowing. The table sets out what the GLP-1 labels say, what alcohol adds, and the source for each side.
| Risk | What the GLP-1 label says | What alcohol adds | Sensible response |
|---|---|---|---|
| Nausea and reflux | Nausea, vomiting and diarrhea are among the most common adverse reactions in the Ozempic and Zepbound labels. | The 2025 joint advisory says alcohol may worsen nausea and reflux on GLP-1 therapy. | Drink less, drink slowly, and skip it when your stomach is already unsettled. |
| Dehydration and kidneys | Both labels report acute kidney injury, mostly in patients whose nausea, vomiting or diarrhea led to dehydration. | A night that ends in vomiting adds fluid loss on top of whatever the medication was already causing. | Alternate with water, and do not drink on days you are already losing fluids. |
| Pancreatitis | Acute pancreatitis has been observed with GLP-1 receptor agonists. Stop the drug if it is suspected. | The NIDDK lists heavy alcohol use as one of the main causes of pancreatitis. | Tell your prescriber about any past pancreatitis or heavy drinking. |
| Low blood sugar | Use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. | MedlinePlus: the liver stops releasing glucose while it processes alcohol, and the risk lasts for hours. | With type 2 diabetes, ask your prescriber first and check glucose. |
Sources: US prescribing information for Ozempic (Novo Nordisk) and Zepbound (Eli Lilly); 2025 ACLM, ASN, OMA and TOS joint advisory; NIDDK; MedlinePlus. This table is not individual medical advice.
The nausea row is the one most people meet first. If your side effects are still settling, our GLP-1 side effects guide explains which ones are common and which are warning signs.
The Two Warnings Worth Taking Seriously
Pancreatitis is the overlap to take most seriously, because it shows up on both sides. The Ozempic and Zepbound labels warn that acute pancreatitis, including fatal hemorrhagic or necrotizing cases, has been observed with GLP-1 receptor agonists. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) names heavy alcohol use as one of the main causes. Nobody has shown that one glass of wine on semaglutide causes pancreatitis. Still, stacking two known risk factors is a poor bet if you already drink heavily or have had pancreatitis before.
The Ozempic label describes the warning sign as severe abdominal pain that may radiate to the back, with or without nausea or vomiting, and tells patients to stop the medication and contact their clinician promptly. That is not a hangover. Treat it as urgent.
Low blood sugar is the second warning, and it matters mainly if you have type 2 diabetes. The labels say the risk rises when a GLP-1 is combined with insulin or an insulin secretagogue such as a sulfonylurea. MedlinePlus, the National Library of Medicine's consumer health service, explains that while your liver is breaking down alcohol it stops releasing glucose, and that the risk of a low remains for hours after your last drink. The dangerous moment is often not at the bar. It is later, asleep. If you take insulin or a sulfonylurea alongside Ozempic or Mounjaro, talk to your prescriber before you drink.
Can Semaglutide Reduce the Urge to Drink?
Semaglutide may reduce how much some people drink, but the evidence is one small trial, not a treatment. In a phase 2 randomized trial published in JAMA Psychiatry in 2025, Hendershot and colleagues gave 48 adults with alcohol use disorder either semaglutide or placebo for nine weeks. The dose was low: 0.25 mg a week for four weeks, 0.5 mg for four weeks, and 1.0 mg only in the final week. Semaglutide reduced the amount of alcohol people drank in a laboratory session, the number of drinks per drinking day, and weekly craving. It did not reduce the number of days people drank.
Experts commenting through the UK Science Media Centre named the limits plainly. The sample was small, the course was too short to reach steady state at 1 mg, and the participants were not trying to cut down. Semaglutide is not FDA-approved for alcohol use disorder. So if the second glass has quietly lost its appeal since you started treatment, you are describing something this trial hints at, nothing more. If drinking is a problem you want help with, raise it with a doctor directly. Medications already approved for alcohol use disorder exist, and a GLP-1 prescribed for weight is not one of them.
If You Do Drink: A Sensible Checklist
If you drink on a GLP-1, the goal is smaller amounts, spaced out, with food and water, and never on a day your stomach is already struggling. None of the steps below has been trialled with GLP-1s specifically. They follow from the label warnings and the guidance above, and your prescriber can adjust them to your situation.
- Count in standard drinks. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines one as 14 grams of alcohol: roughly 12 oz of beer, 5 oz of wine or 1.5 oz of spirits. A restaurant pour of wine is often more than one.
- Eat something first, and keep it small and not greasy. Our guide to foods to avoid on GLP-1 medications covers what sits best.
- Alternate every drink with water. The acute kidney injury warning on both labels is about dehydration, and alcohol on top of vomiting or diarrhea makes it worse.
- Skip alcohol in weeks when nausea is active, which for many people means the stretch right after a dose step. Our guide to your first month on a GLP-1 explains how the dose schedule runs.
- With type 2 diabetes, MedlinePlus advises checking glucose before drinking, while drinking, a few hours after, and for up to the next 24 hours.
- Tell your prescriber honestly how much you drink. Your prescriber cannot weigh a risk they do not know about.
The broader safety warnings on these medications, including the boxed thyroid tumor warning, sit on our GLP-1 safety page. Read it once, then have the alcohol conversation with the person who actually prescribed your pen.
Frequently Asked Questions
The Ozempic prescribing information does not prohibit alcohol and does not list it as an interaction. The 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society says alcohol may worsen nausea and gastroesophageal reflux with GLP-1 therapy and should be minimized. So an occasional drink is not forbidden, but it is not free either. If you have type 2 diabetes, a history of pancreatitis, or you drink heavily, talk to your prescriber before you drink on Ozempic.
We found no published evidence that alcohol stops semaglutide or tirzepatide from working, and neither the Ozempic nor the Zepbound label lists such an interaction. The problem with alcohol on a GLP-1 is indirect. Drinks add calories that do not fill you up, and a few of them tend to loosen the eating habits the medication is helping you build. That undercuts results slowly, through behavior, rather than by blocking the drug.
Drinking on Mounjaro or Ozempic carries a real low blood sugar risk if you also take insulin or a sulfonylurea. The GLP-1 labels say combining them with insulin or an insulin secretagogue can increase the risk of hypoglycemia, including severe hypoglycemia, and MedlinePlus explains that the liver stops releasing glucose while it processes alcohol, with the risk lasting for hours after the last drink. Ask your prescriber before drinking, and check your glucose before, during and up to 24 hours after, as MedlinePlus advises.
Semaglutide reduced craving in one small trial, but it is not a treatment for drinking. In a phase 2 trial published in JAMA Psychiatry in 2025, Hendershot and colleagues gave 48 adults with alcohol use disorder low-dose semaglutide or placebo for nine weeks. Semaglutide cut the alcohol consumed in a laboratory session, drinks per drinking day and weekly craving, but did not reduce the number of drinking days. Semaglutide is not FDA-approved for alcohol use disorder, so bring any drinking concern to a doctor.
Have the Alcohol Conversation With a Clinician
Whether drinking is safe for you on a GLP-1 depends on your other medications, your pancreas history and any diabetes diagnosis, and only a clinician who knows those details can answer it. Licensed online programs include clinicians who can review your full medication list with you.
Prescription required. Medical screening and clinician review required. Not all patients will qualify. Affiliate disclosure: this site may earn a referral fee from programs listed.
Compare Online GLP-1 ProgramsSources
The following sources were used for the label warnings, drinking definitions and trial results referenced on this page. Always verify against the most current version of each document.
- Ozempic (semaglutide) US Prescribing Information, Novo Nordisk, via DailyMed: no alcohol warning; acute pancreatitis warning and symptoms; acute kidney injury mostly in patients with dehydration from gastrointestinal reactions; hypoglycemia risk with insulin or an insulin secretagogue.
- Zepbound (tirzepatide) US Prescribing Information, Eli Lilly, via DailyMed: no alcohol warning; acute pancreatitis and acute kidney injury warnings; hypoglycemia risk with insulin or an insulin secretagogue.
- Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society, 2025: alcohol may worsen nausea and gastroesophageal reflux and should be minimized.
- Hendershot CS et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 2025: 48 participants, nine weeks, reductions in laboratory alcohol consumption, drinks per drinking day and craving, no effect on drinking days.
- Science Media Centre (UK), expert reaction to the JAMA Psychiatry semaglutide alcohol use disorder trial: small sample, short duration, non-treatment-seeking participants.
- National Institute of Diabetes and Digestive and Kidney Diseases, Definition and Facts for Pancreatitis: heavy alcohol use as a main cause.
- MedlinePlus Medical Encyclopedia, Diabetes and alcohol: liver glucose release during alcohol metabolism, delayed low blood sugar, and glucose checks up to 24 hours after drinking.
- National Institute on Alcohol Abuse and Alcoholism, What Is a Standard Drink: 14 grams of alcohol, equivalent to about 12 oz of beer, 5 oz of wine or 1.5 oz of spirits.